Literature DB >> 7086982

Should patients with single renal stone occurrence undergo diagnostic evaluation?

C Y Pak.   

Abstract

Diagnostic evaluation was conducted on 34 patients with a single episode of renal stone formation. Absorptive hypercalciuria as disclosed in 55.9 per cent (23.5 percent type I and 32.4 per cent type II), renal hypercalciuria in 11.8 per cent, primary hyperparathyroidism in 2.9 per cent, hyperuricosuric calcium oxalate nephrolithiasis in 8.8 per cent and no metabolic abnormality in 20.6 per cent. Compared to the group with recurrent stone formation the group with a single stone episode had just as severe biochemical abnormalities or laboratory results, such as hypercalciuria and exaggerated calciuric response to oral calcium load in absorptive hypercalciuria, high fasting urinary calcium and cyclic adenosine monophosphate in renal hypercalciuria, hyperuricosuria in hyperuricosuria calcium oxalate nephrolithiasis and low urine volume in no metabolic abnormality. The results suggest that the same physiological and environmental disturbances characterize stone formation in patients with a single stone episode as in those with recurrent stone formation and indicate the need for diagnostic evaluation.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7086982     DOI: 10.1016/s0022-5347(17)54106-3

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  13 in total

1.  Optimizing the void.

Authors:  Richard W Norman
Journal:  Can Urol Assoc J       Date:  2012-02       Impact factor: 1.862

2.  Arguments for a comprehensive metabolic evaluation of the first-time stone former.

Authors:  Ryan F Paterson
Journal:  Can Urol Assoc J       Date:  2010-06       Impact factor: 1.862

3.  Inaccurate reporting of mineral composition by commercial stone analysis laboratories: implications for infection and metabolic stones.

Authors:  Amy E Krambeck; Naseem F Khan; Molly E Jackson; James E Lingeman; James A McAteer; James C Williams
Journal:  J Urol       Date:  2010-08-21       Impact factor: 7.450

4.  An Increase Incidence in Uric Acid Nephrolithiasis: Changing Patterns.

Authors:  Asha Kumari; Sumit Dokwal; Pawan Mittal; Rajender Kumar; Richa Goel; Piyush Bansal; Himanshu Devender Kumar; Jaikrit Bhutani
Journal:  J Clin Diagn Res       Date:  2016-07-01

Review 5.  Ureteropelvic obstruction and renal stones: etiology and treatment.

Authors:  Andreas Skolarikos; Andreas Dellis; Thomas Knoll
Journal:  Urolithiasis       Date:  2014-11-02       Impact factor: 3.436

6.  Calcium urolithiasis course in young stone formers is influenced by the strength of family history: results from a retrospective study.

Authors:  Angela Guerra; Andrea Ticinesi; Franca Allegri; Antonio Nouvenne; Silvana Pinelli; Fulvio Lauretani; Marcello Maggio; Gianfranco Cervellin; Loris Borghi; Tiziana Meschi
Journal:  Urolithiasis       Date:  2016-12-09       Impact factor: 3.436

7.  24-h urine metabolic profile: is it necessary in all kidney stone formers?

Authors:  Yasmin Abu-Ghanem; Asaf Shvero; Nir Kleinmann; Harry Z Winkler; Dorit E Zilberman
Journal:  Int Urol Nephrol       Date:  2018-06-06       Impact factor: 2.370

Review 8.  Randall's plaques, plugs and the clinical workup of the renal stone patient.

Authors:  Pietro Manuel Ferraro; Ferraro Pietro Manuel; Alessandro D'Addessi; D'Addessi Alessandro; Giovanni Gambaro; Gambaro Giovanni
Journal:  Urolithiasis       Date:  2014-08-06       Impact factor: 3.436

9.  Some features of paediatric urolithiasis in a group of Syrian children.

Authors:  S Hadidy; M Z Shammaa; A Kharma
Journal:  Int Urol Nephrol       Date:  1987       Impact factor: 2.370

10.  Coronary Artery Calcium Score and Association with Recurrent Nephrolithiasis: The Multi-Ethnic Study of Atherosclerosis.

Authors:  Ryan S Hsi; Andrew J Spieker; Marshall L Stoller; David R Jacobs; Alex P Reiner; Robyn L McClelland; Arnold J Kahn; Thomas Chi; Moyses Szklo; Mathew D Sorensen
Journal:  J Urol       Date:  2015-10-08       Impact factor: 7.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.